4//SEC Filing
Lynch Thomas P. 4
Accession 0001209191-17-057221
CIK 0001382911other
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 7:20 PM ET
Size
5.8 KB
Accession
0001209191-17-057221
Insider Transaction Report
Form 4
Lynch Thomas P.
EVP. General Counsel & Sec.
Transactions
- Award
Restricted Stock Unit (RSU)
2017-10-13+69,600→ 69,600 total→ Common Stock (69,600 underlying)
Footnotes (3)
- [F1]Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
- [F2]Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement.
- [F3]Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eligibility on each applicable Vesting Date.
Documents
Issuer
Orexigen Therapeutics, Inc.
CIK 0001382911
Entity typeother
Related Parties
1- filerCIK 0001659824
Filing Metadata
- Form type
- 4
- Filed
- Oct 16, 8:00 PM ET
- Accepted
- Oct 17, 7:20 PM ET
- Size
- 5.8 KB